Skip to main content

Table 1 Demographics and clinical characteristics of subjects included in study 1, 2 and 3

From: Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers

 

Control

sAD

fAD

PA

Study 1

n = 4

n = 4

  

Brain region

Parietal cortex

Parietal cortex

  

Gender (male/female)

1/3

1/3

  

Age at death (years)

64.25 [3.40]

64.50 [2.52]

  

Post-mortem delay, (h)

6.66 [1.19]

5.72 [0.59]

  

Braak stage 0-I/II-IV/V-VI

4/0/0

0/0/4

  

Nlgn1 band signal (F-7 ab)

4425 [419.5]

2374 [914.5]

  
 

Control

sAD

fAD

PA

Study 2

n = 7

n = 9

n = 9

n = 15

Brain region

Temporal cortex

Temporal cortex

Temporal cortex

Temporal cortex

Gender (male/female)

4/3

6/3

3/6

4/11

Age at death (years)

74.14 [18.42]

72.11 [8.3]

52.67 [9.99]

86.33 [5.96]

Post-mortem delay (h)

58.96 [22.77]

71.17 [19.05]

38.8 [17.74]

76.25 [31.08]

Braak stages 0/I-II/III-IV/V-VI

5/2/0/0

0/0/0/9

0/0/0/9

0/4/11/0

Thal phases 0/1–2/3/4–5

5/2/0/0

0/0/0/9

0/0/0/9

0/4/5/6

CERAD score (0/1/2/3)

6/1/0/0

0/0/1/8

0/0/0/9

2/8/5/0

CAA (0/1/2/3)

5/1/1/0

0/4/3/2

0/1/1/7

6/2/6/1

Nlgn1 WB quantification (samples ng/QC ng; 20 µg brain homogenate)

2.22 [0.96]

0.85 [0.57]

0.97 [0.58]

1.78 [0.80]

 

Control

sAD

PSP

CBD

PiD

Study 3

n = 10

n = 10

n = 11

n = 10

n = 9

Brain region

Frontal grey matter

Frontal grey matter

Frontal grey matter

Frontal grey matter

Frontal grey matter

Gender (male/female)

4/6

6/4

6/5

7/3

8/1

Age at death (years)

78.7 [17.65]

69.4 [8.13]

79.27 [9.04]

68.6 [4.93]

69.78 [4.79]

Post-mortem delay, (h)

77.45 [42.8]

56.05 [26.32]

47.93 [21.63]

72.86 [25.05]

67.39 [27.28]

Braak stages 0/I-II/III-IV/V-VI

3/7/0/0

0/0/0/10

na

na

na

Thal phases 0/1–2/3/4–5

4/4/1/1

0/0/0/10

na

na

na

CAA (0/1/2/3)

8/2/0/0

1/1/1/7

na

na

na

Nlgn1 WB quantification

(samples ng/QC ng; 20 µg brain homogenate)

0.92 [0.29]

0.56 [0.35]

0.65 [0.33]

0.45 [0.21]

0.42 [0.27]

  1. The data are presented as mean and [standard deviation]
  2. WB  Western blot, Na  not available, CAA cerebral amyloid angiopathy, 0 = none, 1 = mild, 2 = moderate, 3 = severe